5 275

Cited 3 times in

Effect of Ketoconazole on Lobeglitazone Pharmacokinetics in Korean Volunteers

Authors
 Eun Sil Oh  ;  Choon Ok Kim  ;  Ki Hyon Kim  ;  Youn Nam Kim  ;  Chin Kim  ;  Jangik I. Lee  ;  Min Soo Park 
Citation
 CLINICAL THERAPEUTICS, Vol.36(7) : 1064-1071, 2014 
Journal Title
 CLINICAL THERAPEUTICS 
ISSN
 0149-2918 
Issue Date
2014
MeSH
Adult ; Cross-Over Studies ; Drug Interactions ; Healthy Volunteers ; Humans ; Ketoconazole/administration & dosage* ; Male ; Middle Aged ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects* ; Pyrimidines/pharmacokinetics* ; Republic of Korea ; Thiazolidinediones/administration & dosage ; Thiazolidinediones/adverse effects* ; Thiazolidinediones/pharmacokinetics* ; Young Adult
Keywords
CYP3A4 ; drug interaction ketoconazole ; lobeglitazone ; pharmacokinetics
Abstract
PURPOSE: Lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, is metabolized primarily by the cytochrome P450 (CYP) 3A4 isoenzyme. Individuals concomitantly taking lobeglitazone and a CYP3A4 inhibitor may experience some adverse effects secondary to increased systemic exposure to lobeglitazone. To address such potential concern, we evaluated the effects of ketoconazole, a prototypic CYP3A4 inhibitor, on the pharmacokinetic (PK) properties and associated adverse effects of lobeglitazone. METHODS: A PK drug-drug interaction study was conducted in healthy individuals between 20 and 45 years old in a randomized, open-label, 2-way crossover design. Even though the PK study was performed on a single dose of lobeglitazone, multiple ketoconazole doses were given to ensure that the full extent of inhibition of CYP3A4 was maintained during the PK sampling. All study participants received a single oral dose of lobeglitazone 0.5 mg with or without 9 oral 200-mg doses of ketoconazole pretreatment twice daily. The primary PK parameter end points (AUC and Cmax) were estimated using noncompartmental analysis, and the 90% CIs for the geometric mean ratios (ratio of lobeglitazone and ketoconazole to lobeglitazone alone) were investigated. Tolerability (adverse events, vital signs, ECG, and laboratory tests) was also assessed. FINDINGS: A total of 24 Korean men (mean age, 26 years; age range, 20-32 years; mean weight, 68 kg; weight range, 59-81 kg) completed the study and were evaluable for lobeglitazone PK properties and tolerability. The mean (SD) Cmax values of lobeglitazone with and without ketoconazole were 49 (7) ng/mL and 48 (6) ng/mL at 1.5 and 1.0 hours after dosing, respectively. The mean (SD) AUC∞ values were 532 (117) ng·h/mL and 405 (110) ng·h/mL, respectively. Although the Cmax was not significantly affected, the geometric mean ratio for AUC∞ was increased by a point estimate of 1.33 (90% CI, 1.23-1.44). A single oral administration of lobeglitazone 0.5 mg with or without ketoconazole pretreatment did not produce any clinically significant adverse effects on vital signs, 12-lead ECG profiles, or laboratory tests. IMPLICATIONS: The administration of lobeglitazone, 0.5 mg alone or in combination with multiple doses of ketoconazole, was generally well tolerated. The systemic exposure of lobeglitazone was increased to a modest extent by pretreatment with 9 twice-daily doses of ketoconazole. Clinicaltrials.gov identifier: NCT01330563.
Full Text
http://www.sciencedirect.com/science/article/pii/S0149291814003555
DOI
10.1016/j.clinthera.2014.05.064
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아청소년과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Youn Nam(김윤남)
Kim, Choon Ok(김춘옥) ORCID logo https://orcid.org/0000-0002-2319-1108
Park, Min Soo(박민수) ORCID logo https://orcid.org/0000-0002-4395-9938
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/99700
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse